Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 123 |
| Active Pipeline (Recruiting Now) | 60 (17) |
| Completed vs Stopped Early | 31 / 32 (26.0%) |
| Median Closed Actual Enrollment | 175 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 38 (14 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 27 |
| Hospital Clinic de Barcelona | Barcelona | 25 |
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | 25 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07708727 | Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment | Phase II/III | RECRUITING |
| NCT07682961 | Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral | Phase III | RECRUITING |
| NCT07645287 | A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 | Phase II | RECRUITING |
| NCT07527858 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer | Phase II | RECRUITING |
| NCT06051617 | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Gilead Sciences Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.